Status quo-standard-of-care medical and radiation therapy for glioblastoma

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 12-19

  Becker, Kevin P ^a   Yu, James ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; radiation; temozolomide

Indexed keywords

CARMUSTINE; CHLORMETHINE; DACARBAZINE; LOMUSTINE; MELPHALAN; MITHRAMYCIN; MITOZOLOMIDE; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DNA ALKYLATION; FATIGUE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TUMOR BIOPSY; UNITED STATES;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84863024309     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318244d7eb     Document Type: Review

References (47)

1. CBTRUS. 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in Eighteen States in 2002-2006. 2009-2010. Central brain tumor registry of the US, Hinsdale, IL. www.cbtrus.org.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concom-itant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996. (Pubitemid 40349501)
3. Bennett H, Godlee RJ. Excision of a tumor from the brain. Lancet. 1884; 2:1090-1091.
4. Frankel SA, German WJ. Glioblastoma multiforme; review of219 cases with regard to natural history, pathology, diagnostic methods, and treat-ment. J Neurosurg. 1958;15:489-503.
5. Davis L, Martin J, Goldstein S, et al. A study of 211 patients with verified glioblastomamultiforme. JNeurosurg. 1948;6:33-44.
6. French JD, West PM, Von Amerongen FK, et al. Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg. 1952;9:378-389.
7. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of mithramycin in the treatment ofanaplastic gliomas. J Neurosurg. 1976;44:655-667.
8. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment ofanaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-343. (Pubitemid 9013313)
9. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment ofmalignant glioma after surgery. NEngl JMed. 1980;303:1323-1329. (Pubitemid 11194457)
10. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies ofsupratentorial malignant glioma. J Clin Oncol. 1990; 8:1277-1280. (Pubitemid 20195640)
11. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255-268. (Pubitemid 23276692)
12. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classifica-tion oftumours of the central nervous system. Acta Neuropathol. 2007; 114:97-109. (Pubitemid 47103521)
13. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-724.
14. Carter SK, Friedman MA. 5-(3,3-Dimethyl-L-triazeno)-imidazole-4- carboxamide (DTIC, DIC, NSC-45388)-a new antitumor agent with activity against malignant melanoma. Eur JCancer. 1972;8:85-92.
15. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-D]-1, 2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47: 5846-5852. (Pubitemid 18018717)
16. Newlands ES, Stevens MF, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clin-ical trials. Cancer Treat Rev. 1997;23:35-61. (Pubitemid 27273454)
17. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol. 1987;36:457-462. (Pubitemid 17024167)
18. Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cyto-toxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2- chloroethyl)imidazo[5,1-D]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 1984;44:1772-1775. (Pubitemid 14145712)
19. Scudiero DA, Meyer SA, Clatterbuck BE, et al. Sensitivity of human cell strains having different abilities to repair O -methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res. 1984;44:2467-2474. (Pubitemid 14110669)
20. Baer JC, Freeman AA, Newlands ES, et al. Depletion of O -alkylguanine-DNA alkyltransferase correlates with potentiation oftemozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993;67:1299-1302. (Pubitemid 23172868)
21. Wedge SR, Porteus JK, May BL, et al. Potentiation oftemozolomide and BCNU cytotoxicity by O -benzylguanine: a comparative study in vitro. Br JCancer. 1996;73:482-490. (Pubitemid 26056467)
22. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl JMed. 2005;352: 997-1003. (Pubitemid 40349502)
23. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O -methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871-1874. (Pubitemid 38375541)
24. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. NEngl JMed. 2000;343:1350-1354.
25. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temo-zolomide. Br JCancer. 1992;65:287-291.
26. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A:940-942. (Pubitemid 23126688)
27. Wedge SR, Porteous JK, Glaser MG, et al. In vitro evaluation oftemo-zolomide combined with x-irradiation. Anticancer Drugs. 1997;8:92-97. (Pubitemid 27064756)
28. van Rijn J, Heimans JJ, van den Berg J, et al. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int JRadiat Oncol Biol Phys. 2000;47:779-784. (Pubitemid 30317499)
29. Hirose Y, Berger MS, Pieper RO.Abrogationofthe Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001; 61:5843-5849. (Pubitemid 32769103)
30. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temo-zolomide. J Clin Oncol. 2002;20:1375-1382. (Pubitemid 34177445)
31. Stupp R, Hegi ME, Mason WP, et al. Effects ofradiotherapy with con-comitant and adjuvant temozolomide versus radiotherapy alone on sur-vival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
32. Cardinale R, Won M, Choucair A, et al. A phase II trial ofaccelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006;65:1422-1428. (Pubitemid 44425201)
33. Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment ofmalignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: ajoint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988:279-284. (Pubitemid 18048001)
34. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy JClin Oncol. 2002;20:1635-1642. (Pubitemid 34260545)
35. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int JRadiat Oncol Biol Phys. 2004;60:853-860. (Pubitemid 39311766)
36. Laperriere NJ, Leung PM, Mc Kenzie S, et al. Randomized study of brachytherapy in the initial management ofpatients with malignant as-trocytoma. Int J Radiat Oncol Biol Phys. 1998;41:1005-1011. (Pubitemid 28377480)
37. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison ofsurgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002; 51:343-355; discussion 355-347.
38. Mc Donald MW, Shu HK, Curran WJ Jr, et al. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79:130-136.
39. Urtasun RC, Kinsella TJ, Farnan N, et al. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, phase I-II study. Int JRadiat Oncol Biol Phys. 1996;36:1163-1167.
40. Chang EL, Akyurek S, Avalos T, et al. Evaluation ofperitumoral edema in the delineation of radiotherapy clinical target volumes for glioblas-toma. Int J Radiat Oncol Biol Phys. 2007;68:144-150. (Pubitemid 46589839)
41. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glio-blastoma in the elderly. NEngl JMed. 2007;356:1527-1535.
42. Malmstrom A, Grenberg BH, Stupp R, et al. Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in pa-tients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). JClin Oncol. 2010;28(suppl): Abstract LBA2002.
43. Wick W, Engel C, Combs SE, et al. NOA-08 randomized phase III trial of 1-week-on/1-week-offtemozlomide versus involved-field radiother-apy in elderly (older than age 65) patients wiht newly diagnosed an-aplastic astrocytoma or glioblastoma (methusalem). J Clin Oncol. 2010; 28(suppl):Abstract LBA2001.
44. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583-1588 (Pubitemid 41079795)
45. Radiation therapy with or without temozolomide in treating older pa-tients with newly diagnosed glioblastoma multiforme. www.cancer.gov/ clinicaltrials/search/view?cdrid=547163&version=Health Professional. Accessed 2011.
46. Paravati AJ, Heron DE, Landsittel D, et al. Radiotherapy and temozol-omide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol. 2011;104: 339-349.
47. Shikama N, Sasaki S, Shinoda A, et al. Treatment outcome ofelderly patients with glioblastoma who received combination therapy [published online ahead ofprint May 20, 2011]. Am J Clin Oncol.